123 related articles for article (PubMed ID: 34452904)
1. Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
Feng W; Wang W; Meng R; Wu G; Zhang M; Zhang X; Yin H; Zhu D
BMJ Open Diabetes Res Care; 2021 Aug; 9(1):. PubMed ID: 34452904
[TBL] [Abstract][Full Text] [Related]
2. Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
Yao J; Zhang M; Zhang X; Zhang J
Diabetes Ther; 2023 Apr; 14(4):653-669. PubMed ID: 36809495
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
[TBL] [Abstract][Full Text] [Related]
4. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
Ahrén B; Gautier JF; Berria R; Stager W; Aronson R; Bailey CJ
Diabetes Obes Metab; 2014 Sep; 16(9):861-8. PubMed ID: 24641271
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.
Terauchi Y; Naito Y; Ikeda Y
Diabetes Metab Syndr; 2016; 10(1):23-8. PubMed ID: 26341928
[TBL] [Abstract][Full Text] [Related]
7. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
Eto K; Naito Y; Seino Y
Diabetol Metab Syndr; 2015; 7():106. PubMed ID: 26594250
[TBL] [Abstract][Full Text] [Related]
10. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
Davidson JA; Stager W; Paranjape S; Berria R; Leiter LA
Clin Diabetes Endocrinol; 2020; 6():2. PubMed ID: 31956422
[TBL] [Abstract][Full Text] [Related]
11. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
Meneilly GS; Roy-Duval C; Alawi H; Dailey G; Bellido D; Trescoli C; Manrique Hurtado H; Guo H; Pilorget V; Perfetti R; Simpson H;
Diabetes Care; 2017 Apr; 40(4):485-493. PubMed ID: 28188240
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.
Yabe D; Ambos A; Cariou B; Duvnjak L; Evans M; González-Gálvez G; Lin J; Nikonova EV; de Pablos-Velasco P; Yale JF; Ahrén B
J Diabetes Complications; 2016; 30(7):1385-92. PubMed ID: 27267268
[TBL] [Abstract][Full Text] [Related]
13. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
[TBL] [Abstract][Full Text] [Related]
14. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
Ahrén B; Galstyan G; Gautier JF; Giorgino F; Gomez-Peralta F; Krebs M; Nikonova E; Stager W; Vargas-Uricoechea H
Diabetes Ther; 2016 Sep; 7(3):583-90. PubMed ID: 27319011
[TBL] [Abstract][Full Text] [Related]
15. Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.
Blonde L; Chava P; Dex T; Lin J; Nikonova EV; Goldenberg RM
Diabetes Obes Metab; 2017 Feb; 19(2):275-283. PubMed ID: 27767249
[TBL] [Abstract][Full Text] [Related]
16. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.
Seino H; Onishi Y; Naito Y; Komatsu M
Diabetol Metab Syndr; 2016; 8():36. PubMed ID: 27252787
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M
J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920
[TBL] [Abstract][Full Text] [Related]
18. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Trujillo JM; Goldman J
Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
[TBL] [Abstract][Full Text] [Related]
19. Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.
Shu H; Gu LN; Men LC; Lu JM
Diabetes Ther; 2016 Dec; 7(4):777-792. PubMed ID: 27796905
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
Raccah D
Expert Rev Endocrinol Metab; 2013 Mar; 8(2):105-121. PubMed ID: 30736171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
